Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US

BACKGROUND: February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Juday, Timothy, Correll, Todd, Anene, Ayanna, Broder, Michael S, Ortendahl, Jesse, Bentley, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770712/
https://www.ncbi.nlm.nih.gov/pubmed/24039438
http://dx.doi.org/10.2147/CEOR.S47486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770712/
https://www.ncbi.nlm.nih.gov/pubmed/24039438
http://dx.doi.org/10.2147/CEOR.S47486

Ejemplares similares